Deals this week: BioMarin Pharmaceutical, Spectrum Pharmaceuticals, Orient Pharma

US-based biotechnology company BioMarin Pharmaceutical has announced the completion of an underwritten public offering of senior subordinated convertible notes to raise $450m.

The notes carry a rate of 0.599% and are due on 1 August 2024.

BioMarin plans to use the funds to repay debt, repurchase notes due in October 2018, as well as for general corporate purposes.

Spectrum Pharmaceuticals plans for a private placement of shares to raise up to $150m.

The US-based biopharmaceutical company plans to use the funds towards general corporate purposes.

Chinese pharmaceutical company Orient Pharma plans to issue 21 million common stock shares priced at NT$20 ($D0.6) each to raise NT$425m ($14.06m).

The company plans to use the funds towards loan repayment and for working capital purposes.